Share on StockTwits
 

Isis Pharmaceuticals (NASDAQ:ISIS)‘s stock had its “positive” rating reaffirmed by Needham & Company in a research note issued on Friday, StockRatingsNetwork.com reports. They currently have a $61.00 price target on the stock, up from their previous price target of $46.00. Needham & Company’s price target indicates a potential upside of 3.39% from the company’s current price.

A number of other firms have also recently commented on ISIS. Analysts at Canaccord Genuity raised their price target on shares of Isis Pharmaceuticals from $32.00 to $45.00 in a research note on Thursday. They now have a “hold” rating on the stock. Separately, analysts at Deutsche Bank initiated coverage on shares of Isis Pharmaceuticals in a research note on Wednesday, January 22nd. They set a “buy” rating and a $60.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note on Tuesday, January 21st. They now have a $49.00 price target on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $39.36.

Isis Pharmaceuticals (NASDAQ:ISIS) opened at 59.00 on Friday. Isis Pharmaceuticals has a one year low of $13.76 and a one year high of $61.30. The stock’s 50-day moving average is $48.35 and its 200-day moving average is $37.14. The company’s market cap is $6.848 billion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.